

# Elena Rossi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/275766/publications.pdf>

Version: 2024-02-01

115  
papers

3,624  
citations

182225

30  
h-index

156644

58  
g-index

117  
all docs

117  
docs citations

117  
times ranked

3746  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 939-949.	2.3	6
2	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study. <i>British Journal of Haematology</i> , 2022, 197, 190-200.	1.2	7
3	A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. <i>Blood Advances</i> , 2022, 6, 1855-1864.	2.5	47
4	Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. <i>Blood Cancer Journal</i> , 2022, 12, 28.	2.8	31
5	Large-scale analysis of SARS-CoV-2 synonymous mutations reveals the adaptation to the human codon usage during the virus evolution. <i>Virus Evolution</i> , 2022, 8, veac026.	2.2	15
6	Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group. <i>Annals of Hematology</i> , 2022, 101, 1275-1282.	0.8	2
7	Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis. <i>Cancers</i> , 2022, 14, 1799.	1.7	0
8	Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series. <i>Hematological Oncology</i> , 2021, 39, 123-128.	0.8	1
9	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	1.2	19
10	Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis. <i>Annals of Hematology</i> , 2021, 100, 105-116.	0.8	4
11	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	2.8	41
12	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 21.	2.8	26
13	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	2.0	14
14	Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. <i>Leukemia</i> , 2021, 35, 2989-2993.	3.3	34
15	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. <i>American Journal of Hematology</i> , 2021, 96, 1472-1480.	2.0	20
16	From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox. <i>Frontiers in Oncology</i> , 2021, 11, 752192.	1.3	7
17	Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera. <i>Blood</i> , 2021, 138, 1499-1499.	0.6	1
18	JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. <i>Blood Cancer Journal</i> , 2021, 11, 199.	2.8	47

#	ARTICLE	IF	CITATIONS
19	Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin. <i>Leukemia</i> , 2020, 34, 1208-1209.	3.3	1
20	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , 2020, 95, 156-166.	2.0	53
21	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	2.0	106
22	Second cancers in MPN: Survival analysis from an international study. <i>American Journal of Hematology</i> , 2020, 95, 295-301.	2.0	34
23	A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation. <i>Leukemia Research</i> , 2020, 97, 106441.	0.4	8
24	Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. <i>HemaSphere</i> , 2020, 4, e497.	1.2	14
25	Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3900.	1.8	12
26	Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-world practice. <i>Annals of Hematology</i> , 2020, 99, 65-72.	0.8	13
27	Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1535-1547.	0.6	6
28	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	0.8	15
29	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. <i>Blood</i> , 2020, 135, 381-386.	0.6	18
30	Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients. <i>Blood</i> , 2020, 136, 42-43.	0.6	8
31	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. <i>Blood</i> , 2020, 136, 171-182.	0.6	65
32	Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study. <i>Blood Research</i> , 2020, 55, 139-145.	0.5	2
33	Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. <i>Blood</i> , 2020, 136, 17-18.	0.6	1
34	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. <i>Blood</i> , 2020, 136, 49-50.	0.6	0
35	First Line Treatment with Hydroxyurea in Patients with Polycythemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. <i>Blood</i> , 2020, 136, 43-44.	0.6	0
36	Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach. <i>Hematological Oncology</i> , 2019, 37, 424-433.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. <i>Leukemia</i> , 2019, 33, 1996-2005.	3.3	67
38	Deferasirox in the management of iron overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (<sc>IRON</sc> study). <i>British Journal of Haematology</i> , 2019, 186, e123-e126.	1.2	10
39	Treatment of Philadelphia negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. <i>Hematological Oncology</i> , 2019, 37, 291-295.	0.8	14
40	Management and outcome of 11 pregnancies in women with polycythemia vera. <i>Leukemia Research</i> , 2019, 81, 25-26.	0.4	2
41	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	0.8	3
42	Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. <i>Blood Advances</i> , 2019, 3, 3196-3200.	2.5	18
43	Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. <i>Frontiers in Oncology</i> , 2019, 9, 1186.	1.3	142
44	PS1468 IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS. <i>HemaSphere</i> , 2019, 3, 667-668.	1.2	0
45	PF674 OUTCOME OF PATIENTS WITH MYELOFIBROSIS AFTER RUXOLITINIB DISCONTINUATION: ROLE OF DISEASE STATUS AND TREATMENT STRATEGIES IN 218 PATIENTS. <i>HemaSphere</i> , 2019, 3, 290.	1.2	4
46	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. <i>Blood</i> , 2019, 134, 839-839.	0.6	2
47	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. <i>Blood</i> , 2019, 134, 4170-4170.	0.6	2
48	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019, 134, 4166-4166.	0.6	0
49	Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. <i>Blood</i> , 2019, 134, 4188-4188.	0.6	0
50	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4184-4184.	0.6	1
51	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4174-4174.	0.6	2
52	Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients. <i>Blood</i> , 2019, 134, 1714-1714.	0.6	0
53	Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine Results from the Italian "Back to Life" project. <i>Quality of Life Research</i> , 2018, 27, 1545-1554.	1.5	9
54	Iron toxicity " Its effect on the bone marrow. <i>Blood Reviews</i> , 2018, 32, 473-479.	2.8	46

#	ARTICLE	IF	CITATIONS
55	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 25.	2.8	26
56	JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib. <i>Human Pathology</i> , 2018, 73, 171-175.	1.1	10
57	Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. <i>American Journal of Hematology</i> , 2018, 93, 58-64.	2.0	31
58	Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. <i>Blood Cancer Journal</i> , 2018, 8, 112.	2.8	55
59	The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. <i>Future Oncology</i> , 2018, 14, 2713-2723.	1.1	9
60	The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2018, 182, 701-704.	1.2	22
61	Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea. <i>Blood Cancer Journal</i> , 2018, 8, 56.	2.8	6
62	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. <i>Blood Cancer Journal</i> , 2018, 8, 49.	2.8	30
63	Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 4279-4279.	0.6	1
64	Effects of the Switch to Generic Imatinib in a Cohort of 109 Italian CML Patients - the Gims Study. <i>Blood</i> , 2018, 132, 4266-4266.	0.6	2
65	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018, 132, 4277-4277.	0.6	11
66	Presentation and Outcome of 199 Patients with 2016 WHO Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018, 132, 3052-3052.	0.6	0
67	Management and Outcome of 11 Pregnancies in Women with Polycythemia Vera. <i>Blood</i> , 2018, 132, 5471-5471.	0.6	0
68	Integrating Clinical, Morphological, and Molecular Data to Assess Prognosis in Patients with Primary Myelofibrosis: A Practical Approach. <i>Blood</i> , 2018, 132, 1766-1766.	0.6	0
69	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. <i>Blood</i> , 2018, 132, 4303-4303.	0.6	3
70	Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. <i>Thrombosis and Haemostasis</i> , 2016, 115, 240-249.	1.8	76
71	High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. <i>Leukemia</i> , 2016, 30, 2032-2038.	3.3	75
72	Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. <i>American Journal of Hematology</i> , 2016, 91, 692-699.	2.0	54

#	ARTICLE	IF	CITATIONS
73	Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. <i>Blood Cancer Journal</i> , 2016, 6, e493-e493.	2.8	80
74	Neurological symptoms in essential thrombocythemia: impact of JAK2V617F mutation and response to therapy. <i>European Journal of Haematology</i> , 2016, 96, 593-601.	1.1	7
75	Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN. <i>Blood</i> , 2016, 128, 1951-1951.	0.6	3
76	Latium (Italy) Epidemiology of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) from 2011 to 2015: A Prospective Analysis from Gruppo Laziale of Ph Negative MPN. <i>Blood</i> , 2016, 128, 5473-5473.	0.6	0
77	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. <i>Blood</i> , 2015, 125, 499-503.	0.6	115
78	GOOD OUTCOME FOR VERY HIGH RISK ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA CARRYING GENETIC ABNORMALITIES t(4;11)(q21;q23) or t(9;22)(q34;q11), IF PROMPTLY SUBMITTED TO ALLOGENEIC TRANSPLANTATION, AFTER OBTAINING A GOOD MOLECULAR REMISSION.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015041.	0.5	5
79	Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia. <i>Internal and Emergency Medicine</i> , 2015, 10, 451-460.	1.0	7
80	Thrombopoietin Receptor Agonist (TPO-RA) Switch in Adult Primary Immune Thrombocytopenia (ITP) Patients: A Retrospective Collaborative Survey from 8 Italian Hematology Centers. <i>Blood</i> , 2015, 126, 3462-3462.	0.6	2
81	IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014042.	0.5	17
82	Cerebral vein thrombosis in patients with Philadelphia chromosome-negative myeloproliferative neoplasms An European Leukemia Network study. <i>American Journal of Hematology</i> , 2014, 89, E200-5.	2.0	42
83	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. <i>British Journal of Haematology</i> , 2014, 167, 541-546.	1.2	47
84	Venous Thromboembolism in Multiple Myeloma. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 338-347.	1.5	59
85	Risk Factor and Etiology Analysis of Ischemic Stroke in Young Adult Patients. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, e221-e227.	0.7	69
86	Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. <i>American Journal of Hematology</i> , 2014, 89, 306-309.	2.0	50
87	Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2212-2212.	0.6	0
88	A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis. <i>Blood</i> , 2014, 124, 3188-3188.	0.6	0
89	Development of JAK2V617F-Positive Polycythemia Vera after Chemotherapy-Induced Remission of Primary Central Nervous System Diffuse Large B Cell Non-Hodgkin's Lymphoma: A Case Report and Review of the Literature. <i>Acta Haematologica</i> , 2013, 130, 142-145.	0.7	3
90	Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. <i>British Journal of Haematology</i> , 2013, 160, 673-679.	1.2	23

#	ARTICLE	IF	CITATIONS
91	Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. <i>New England Journal of Medicine</i> , 2013, 368, 22-33.	13.9	664
92	Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects. <i>Blood</i> , 2013, 122, 1582-1582.	0.6	1
93	Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms. <i>Blood</i> , 2013, 122, 4068-4068.	0.6	10
94	A CASE OF ATYPICAL PROLONGED HEMATOLOGIC TOXICITY WITH AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML), REVIEW OF LITERATURE AND A PROPOSAL OF MANAGEMENT. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012017.	0.5	1
95	Hydroxyurea-related toxicity in 3,411 patients with Ph <sup>-</sup> negative MPN. <i>American Journal of Hematology</i> , 2012, 87, 552-554.	2.0	105
96	Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146 <sup>+</sup> immunomagnetic enrichment <sup>+</sup> flow cytometry and soluble E-selectin detection. <i>American Journal of Hematology</i> , 2012, 87, 319-320.	2.0	18
97	How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort. <i>Blood</i> , 2012, 120, 1748-1748.	0.6	1
98	A Large-Scale Trial Testing the Intensity of Cytoreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial). <i>Blood</i> , 2012, 120, 4-4.	0.6	3
99	Blood Cells Dynamic and Thrombo-Haemorrhagic Events in Low Risk Essential Thrombocytosis Patients. A North Italian and Austrian Study.. <i>Blood</i> , 2012, 120, 2839-2839.	0.6	0
100	In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband. <i>Thrombosis and Haemostasis</i> , 2011, 106, 646-654.	1.8	28
101	JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis. <i>American Journal of Hematology</i> , 2011, 86, 526-528.	2.0	31
102	Development of Polycythemia Vera after Chemotherapy-Induced Remission of Acute Myeloid Leukemia: A Case Report. <i>Acta Haematologica</i> , 2011, 126, 52-53.	0.7	9
103	Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. <i>American Journal of Hematology</i> , 2010, 85, 97-100.	2.0	48
104	Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. <i>Annals of Hematology</i> , 2010, 89, 141-146.	0.8	39
105	A case of Philadelphia Positive Acute Lymphoblastic Leukaemia with three different phenotypic lineage, each one presenting the same BCR-ABL hybrid transcript. <i>Leukemia Research</i> , 2009, 33, e175-e177.	0.4	0
106	Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. <i>Haematologica</i> , 2009, 94, 733-737.	1.7	51
107	Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. <i>Haematologica</i> , 2008, 93, 372-380.	1.7	316
108	The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia. <i>Thrombosis and Haemostasis</i> , 2008, 99, 1030-1034.	1.8	32



#	ARTICLE	IF	CITATIONS
109	Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia. <i>Clinical Leukemia</i> , 2007, 1, 339-344.	0.2	1
110	Successful treatment with T depleted autologous peripheral blood stem cell transplantation of refractory chronic autoimmune thrombocytopenic purpura. <i>Haematologica</i> , 2007, 92, e7-e8.	1.7	6
111	Prophylaxis and Treatment of Venous Thromboembolism in Individuals with Inherited Thrombophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 767-780.	1.5	31
112	Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. <i>Transfusion</i> , 2005, 45, 1214-1220.	0.8	14
113	Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. <i>Transplant Infectious Disease</i> , 2005, 7, 122-125.	0.7	44
114	Prothrombin G20210A Mutant Genotype Is a Risk Factor for Cerebrovascular Ischemic Disease in Young Patients. <i>Blood</i> , 1998, 91, 3562-3565.	0.6	222
115	Prothrombin G20210A Mutant Genotype Is a Risk Factor for Cerebrovascular Ischemic Disease in Young Patients. <i>Blood</i> , 1998, 91, 3562-3565.	0.6	6